Stockscreener 앱 받기
1.87
8.72%
0.15
시간 외 거래:
1.89
0.02
+1.07%
전일 마감가:
$1.72
열려 있는:
$1.71
하루 거래량:
1.89M
Relative Volume:
0.99
시가총액:
$331.06M
수익:
$137.74M
순이익/손실:
$-27.97M
주가수익비율:
-11.69
EPS:
-0.16
순현금흐름:
$-9.61M
1주 성능:
-13.82%
1개월 성능:
-2.60%
6개월 성능:
+57.14%
1년 성능:
-37.67%
1일 변동 폭
$1.71
$1.88
1주일 범위
$1.70
$2.255
52주 변동 폭
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
명칭
Heron Therapeutics Inc
전화
(858) 251-4400
주소
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
HRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.87 | 331.06M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2024-04-23 | 개시 | CapitalOne | Overweight |
| 2024-03-13 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Buy |
| 2020-02-20 | 재확인 | Needham | Buy |
| 2019-01-16 | 재확인 | Needham | Buy |
| 2018-04-05 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2018-03-01 | 재확인 | Needham | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Outperform |
| 2017-09-27 | 개시 | Northland Capital | Outperform |
| 2017-02-27 | 개시 | Needham | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-09-06 | 재개 | Lake Street | Buy |
| 2016-05-03 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-10 | 개시 | Lake Street | Buy |
| 2015-09-23 | 재확인 | Leerink Partners | Outperform |
| 2015-09-02 | 개시 | BofA/Merrill | Buy |
| 2015-08-03 | 재확인 | Brean Capital | Buy |
| 2015-06-30 | 재확인 | JMP Securities | Mkt Outperform |
| 2015-06-19 | 재확인 | Leerink Partners | Outperform |
| 2014-08-07 | 개시 | Noble Financial | Buy |
모두보기
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
J. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLC - MarketBeat
What is Northland Capmk's Estimate for HRTX Q2 Earnings? - MarketBeat
Clearline Capital LP Has $2.77 Million Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Heron Therapeutics Sees Unusually Large Options Volume (NASDAQ:HRTX) - MarketBeat
Results: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (NASDAQ:HRTX) - Seeking Alpha
Heron settles patent dispute with Viatris over antiemetic agents - MSN
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Heron Therapeutics Reports Strong Q1 2025 Results - TipRanks
Heron Therapeutics Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Heron Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) Resolves Patent Dispute with Viatris - GuruFocus
Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise - marketscreener.com
Heron stock up as Viatris patent dispute ends (HRTX:NASDAQ) - Seeking Alpha
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surges - Investing.com Canada
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
HRTX Achieves Record Q1 Revenue, Surpassing Expectations | HRTX Stock News - GuruFocus
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates - The Malaysian Reserve
Heron Therapeutics (HRTX) Settles Patent Disputes with Mylan Pharmaceuticals | HRTX Stock News - GuruFocus
Heron Therapeutics Q1 2025 Financial Results - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Heron Therapeutics settles patent litigation with Mylan By Investing.com - Investing.com India
Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations - marketscreener.com
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PR Newswire
Invesco Ltd. Grows Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics (HRTX) Awaits Q1 Earnings Report - GuruFocus
Marshall Wace LLP Cuts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Renaissance Technologies LLC Has $1.82 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by LPL Financial LLC - Defense World
Healthy Upside Potential: Heron Therapeutics Inc (HRTX) - Sete News
American Society of Anesthesiologists Announces Heron Therapeutics as Industry Supporter for Seventh Year | Newswise - Newswise
HRTX stock rated a Buy by Rodman & Renshaw - knoxdaily.com
It would be worthwhile to take a closer look at Heron Therapeutics Inc (HRTX) - uspostnews.com
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Heron Therapeutics Appoints Mark Hensley as COO - TipRanks
Heron Therapeutics Names Mark Hensley as COO - marketscreener.com
Heron Therapeutics Inc (HRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.45%
자본화:
|
볼륨(24시간):